Bis(maltolato)oxovanadium(IV)
Modify Date: 2024-01-02 14:46:06
Bis(maltolato)oxovanadium(IV) structure
|
Common Name | Bis(maltolato)oxovanadium(IV) | ||
|---|---|---|---|---|
| CAS Number | 38213-69-3 | Molecular Weight | 317.145 | |
| Density | N/A | Boiling Point | 284.7ºC at 760mmHg | |
| Molecular Formula | C12H10O7V | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 127.3ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of Bis(maltolato)oxovanadium(IV)Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer[1][2]. |
| Name | Bis(maltolato)oxovanadium(IV) |
|---|---|
| Synonym | More Synonyms |
| Description | Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 126 nM (HCPTPA), 109 nM (PTP1B), 26 nM (HPTPβ) and 201 nM (SHP2)[2] |
| In Vitro | Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells[1]. |
| In Vivo | Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice[1]. Animal Model: C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD)[1] Dosage: 0.75-3.0 mmol Administration: Intraperitoneal injection; twice weekly; for 6 weeks Result: Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance. |
| References |
| Boiling Point | 284.7ºC at 760mmHg |
|---|---|
| Molecular Formula | C12H10O7V |
| Molecular Weight | 317.145 |
| Flash Point | 127.3ºC |
| Exact Mass | 316.986603 |
| PSA | 95.95000 |
| LogP | 1.46380 |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Hazard Codes | T+ |
| RIDADR | UN 2811 6.1 / PGIII |
| Oxovanadium(2+) bis(2-methyl-4-oxo-4H-pyran-3-olate) |
| 2-methyl-4-oxopyran-3-olate,oxovanadium(2+) |